![]() ![]() of canrenone for at least two days of continuous administration) showed an event-free rate of 80% with a survival rate of 87%. Group B (given a mean dose of 200 mg/q.d. ![]() (group A) had an event-free rate of 51% and a survival rate of 64%. Group A (n = 39) were given vasodilator agents or renin-angiotensin-aldosterone system (RAAS) inhibitors and group B (n = 30) were given canrenone i.v.ResultsAmong the 69 consecutive COVID-19 patients, those not receiving canrenone i.v. on the need of invasive ventilatory support and/or all-cause in-hospital mortality.MethodsSixty-nine consecutive COVID-19 patients, hospitalized for moderate to severe respiratory failure at Fondazione Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico of Milan, received two different therapeutic approaches in usual care according to the personal skills and pharmacological management experience of the referral medical team. BackgroundIn COVID-19 patients, aldosterone via angiotensin-converting enzyme-2 deregulation may be responsible for systemic and pulmonary vasoconstriction, inflammation, and oxidative organ damage.AimTo verify retrospectively the impact of the mineralcorticoid receptor antagonist canrenone i.v. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |